-

Verantos Ranked Number 444th Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

MENLO PARK, Calif.--(BUSINESS WIRE)--Verantos today announced it ranked 444 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. It was the only real-world evidence-focused company on the list.

Verantos was the only real-world evidence-focused company on the Fast 500 list.

Share

“Real-world evidence is increasingly used to augment trial results, providing insight on patient subgroups and real-world outcomes,” Verantos’ chief executive officer, Dan Riskin, said. “As such evidence has become more prominent, life sciences and evidence consumers have increased their scrutiny of evidence validity. In parallel, an artificial intelligence revolution has shined a light on the importance of data quality. As a leader in healthcare data quality, Verantos is particularly well-positioned in high-validity real-world evidence.”

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology that significantly contributes to the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million, with a growth rate of 50% or greater. Additionally, companies must be in business for a minimum of four years and be headquartered within North America (United States and Canada).

“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”

About Verantos

Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to the complete patient record, Verantos enables life sciences organizations to generate high-validity evidence across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives.

About the 2025 Deloitte Technology Fast 500

Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2021 to 2024.

Contacts

Media contact
Dan West
marketing@verantos.com

Verantos


Release Versions

Contacts

Media contact
Dan West
marketing@verantos.com

Social Media Profiles
More News From Verantos

Verantos to Present Practical Approaches in High-Validity Real-World Evidence Generation at ISPE’s 41st Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence at scale, announced today that it will present practical approaches for generating high-validity real-world evidence (RWE) at the International Society for Pharmacoepidemiology (ISPE) 41st Annual Meeting in Washington, D.C. CEO Dan Riskin will share approaches to achieve fit-for-use RWD based on real-world learnings from large pharma collaborations and the FDA-sponsored Verantos-led TRUST and V...

Verantos Named to Inc. 5000 List for the Fourth Consecutive Year

PALO ALTO, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence (RWE) for the life sciences, marks its fourth consecutive appearance on the Inc. 5000, ranking No. 2405 on the most prestigious list of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft,...

Verantos-led Study in JAMA Network Open Demonstrates a Defined Approach to Measure and Optimize Data Reliability

PALO ALTO, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence at scale, today announced the publication “Implementing Accuracy, Completeness, and Traceability for Data Reliability” in JAMA Network Open. The study, written in collaboration with a consortium of academic and industry leaders, proposes a reproducible framework for measuring and optimizing the reliability of real-world data (RWD). In 2024, the FDA published the final guidance document “Real-Wor...
Back to Newsroom